43 results about "Tissue factor" patented technology

The invention discloses a thrombelastogram detection reagent as well as a preparation method and application thereof. The thrombelastogram detection reagent is prepared from the following components: an activator, phospholipid, a buffer solution, a surfactant, a stabilizer, a preservative and a tissue factor, the invention further discloses a specific preparation method. According to the reagent disclosed by the invention, the complexity and variability of blood coagulation are fully considered, the reagent with relatively high accuracy and precision is obtained by adjusting the composition of the components, and the reagent has good clinical use value and economic value.

Disclosed are methods and compositions related to chimeric antigen receptors (CARs) that recognize Tissue Factor (TF). Specifically, disclosed are CARs that comprise fVII or a functional fragment thereof. Also disclosed are immune effector cells comprising the CARs disclosed herein.

The present invention provides a mesenchymal stem cell having blood compatibility, and a preparation method and use thereof, the mesenchymal stem cell inducing exon skipping of an exon 5 by performing gene modification on the exon 5 of an F3 gene, thereby increasing the expression of a selective splicing tissue factor (asTF), and improving the blood compatibility of the mesenchymal stem cell. The present invention relates to a method for inhibiting thrombosis by reducing or inhibiting the expression or activity level of a full-length tissue factor (flTF), which is a blood coagulation promoter, and thereby inhibiting thrombosis.

The invention belongs to the technical field of medicines, and discloses application of pantethine in preparation of medicines for preventing and / or treating thrombotic diseases or medicines for inhibiting platelet activation or regulating vascular endothelial cell functions. In-vivo and in-vitro experiments prove that pantethine can remarkably relieve thrombus load in a mouse thrombus model, down-regulate expression of vWF (von Willebrand Factor), up-regulate expression of TFPI (Tissue Factor Path Inhibitor) and TH BD (Thromboregulatory Protein), and antagonize platelet adhesion, aggregation and activation induced by a platelet activator. The action mechanism is closely related to inhibition of reactive oxygen species (ROS) generation and NF-kappa B signal channel activation, and improvement of endothelial cell functions. It can be known from the invention that pantethine plays an antithrombotic role from multiple aspects, and is suitable for preparation of antithrombotic drugs for prevention or treatment. The invention provides a new drug choice for prevention and treatment of thrombotic diseases.

The present invention relates to single domain antibodies (sdAbs) against TREM (triggering receptors expressed on myeloid cells) like transcript-1 (TLT-1) molecules that are present on activated platelets at the site of an injury, and especially on a subset of activated platelets, coated platelets. Furthermore, the present invention relates to fusion proteins comprising sdAbs against TLT-1 and an extracellular (soluble) domain of tissue factor (sTF), to direct targeting of such fusion proteins to activated platelets at the site of injury through binding of the sdAbs to TLT-1, a membrane protein receptor that is only present on activated platelets. Specific interaction of sdAbs with the TLT-1 receptor positions the sTF domain of the fusion to interact with, and activate, FVII. As a result, a targeted procoagulant effect is achieved at the site of injury via activated platelets. The fusion proteins are useful to treat individuals that have a bleeding disorder, such as hemophilia A, hemophilia B, or acute bleeding due to traumatic injury.

Disposable cartridges and methods for detecting and classifying an anticoagulant at a therapeutically relevant amount or higher in a patient. The cartridges include a plurality of chambers, as well as fluidic couplings between chambers. Calcium chloride, Russel Viper Venom (RVV), an ecarin reagent, a Factor Xa reagent, protamine, kaolin, tissue factor, and combinations thereof may be included in a given chamber.

The present application relates to tissue factor binding antibodies and uses thereof, in particular to an antibody or antigen binding fragment thereof specifically binding to TF, and a kit containing the antibody or antigen binding fragment, the antibody or antigen binding fragment comprising: (i) LCDR1, LCDR2 and LCDR3 sequences of a light chain variable region as shown in SEQ ID NO: 1, and (ii) HCDR1, HCDR2 and HCDR3 sequences of a heavy chain variable region as shown in SEQ ID NO: 2, wherein the CDR is defined according to IMGT, Kabat, Chothia or Contact or any combination thereof. The tissue factor binding antibody provided by the present application has high sensitivity, high accuracy and high precision, and can meet the demand for accurate detection of tissue factor.

Embodiments of the disclosure include methods and compositions for the treatment of instant blood-mediated inflammatory reaction. In specific embodiments, fibroblasts, and / or fibroblast-derived materials, are utilized in at least some cases to effect the expression of tissue factor in the cells of the individual or of the cells placed within the individual.

Disclosed is a method for evaluation of residual platelet thrombotic potential in a patientundergoing antiplatelet therapy with acetylsalicylic acid which comprises determination ofplatelet tissue factor (TF) expression in a patient's blood sample.

The present invention relates to the technical field of biopharmaceuticals, and provides an anti-tissue factor humanized antibody, a prepared antibody-drug conjugate, and a use. An amino acid sequence of a heavy chain of the anti-tissue factor humanized antibody is as shown in SEQ ID NO: 3, and an amino acid sequence of a light chain of the anti-tissue factor humanized antibody is as shown in SEQ ID NO: 4. The anti-tissue factor humanized antibody has high affinity to tissue factors. The present invention further provides an antibody-drug conjugate, which is obtained by coupling the anti-tissue factor humanized antibody to a cytotoxic drug. On the basis of the characteristics that the anti-tissue factor humanized antibody has high affinity and short cell endocytosis time for tumor cell strains with low-expression and high-expression tissue factors, the antibody-drug conjugate can quickly reach a tumor target to achieve cytotoxicity, and can effectively inhibit the growth of tumor cells and subcutaneous tumor growth of mice. Therefore, the antibody-drug conjugate plays an important role in cancer treatment.

The application provides a multi-specific antibody monomer having a light chain (LC) and a heavy chain (HC), each having a N-terminal and a C-terminal, comprising, a first scFv domain having a binding affinity to a tumor-associated antigen (TAA) at the N-terminal of the HC (Position 1, or P1), a Fab domain having a binding affinity to CD3, and a second scFv domain having a binding affinity to PD-L1 at the C-terminal of the LC (Position 5, or P5) or the N-terminal of the LC (Position 6, or P6). In some embodiments, the TAA comprises EGFR, HER3, DLL3, HER2, GPC3, HLA-G, uPAR, Nectin4, Fra, Tissue Factor, B7-H4, VEGFR2, B7-H3, Muc16, CEACAM6, Claudin6, CLDN18.2, LGR5, GCC, CD20, CD19, Integrin β6, Muc1, CDH6, FAP, CAIX, Integrin β4, CDH17, Lewis B / Y, GPRC5D, CEACAM5, ROR1, or EGFR vIII.

The present invention relates to an antibody and an antibody-drug conjugate, and particularly to an antibody and an antibody-drug conjugate (ADC) targeting the tissue factor, and a composition comprising the antibody or ADC, and a therapeutic application thereof.

Provided herein are single-chain chimeric polypeptides comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a second target binding domain. Also provided herein are methods of using these single-chain chimeric polypeptides and nucleic acids encoding these single-chain chimeric polypeptides.

The invention relates to single-chain chimeric polypeptides and uses thereof. Provided herein are single chain chimeric polypeptides comprising: (i) a first target binding domain; (ii) a soluble tissue factor domain; and (iii) a second target binding domain. Also provided herein are methods of using the single-stranded chimeric polypeptides and nucleic acids encoding the single-stranded chimeric polypeptides.

A kit comprising a predetermined amount of tissue factor and phospholipids in a container; a predetermined amount of the tissue factor, phospholipids and activated protein C in a second container; and a container comprising a test solution; uses of the kit; and methods for predicting the risk of pulmonary thromboembolism.

Intracerebral hemorrhage (ICH), defined as spontaneous bleeding into the brain, is the deadliest, most disabling, and least treatable form of stroke. The aim of the present invention is to generate large amount of hemostatic mEVs to be used as hemostatic patches in different preclinical models of ICH. Indeed, the exogenous mEVs pf the present invention bearing TF and PSGL-1 improve outcome after collagenase-induced ICH by acting as intravascular hemostatic patches. The present invention thus relates to monocyte extracellular vesicles (mEVs) functionalized with tissue factor (TF) and P-Selectin Glycoprotein Ligand 1 (PSGL-1).

Use of inducible vesicles in the preparation of extracorporeal blood coagulation promoters or extracorporeal hemostatic agents. The inducible vesicles are obtained by adding an apoptosis inducer and contacting them with stem cells or somatic cells. Expression of tissue factor is an important factor for the inducible vesicles to achieve extracorporeal blood coagulation promoters or extracorporeal hemostatic agents.

The application discloses a preparation method and product of a thromboelastography rapid detection cup reagent, and comprises the following steps: adding purified water into washed or calcined kaolin, adding glycine, mannitol, dextran and bovine serum albumin while stirring, and then adding a Tris-HCl system to adjust the pH to 6.5-7.8; finally, adding a recombinant lipidized tissue factor and uniformly stirring to obtain the reagent; wherein, the content of the washed or calcined kaolin is 0.01-0.8% based on 100% of the mass of each raw material, the content of the glycine is 2-6%, the content of the mannitol is 4-8%, the content of the dextran is 2-6%, the content of the bovine serum albumin is 0.2-5%, the content of the recombinant lipidized tissue factor is 0.2-1.5%, and the balance is made up to 100% by the purified water. The application provides a preparation method of the thromboelastography rapid detection cup reagent, and the prepared reagent can be stored for a long time, has good stability, and has good freeze-drying form and solubility.

A nucleic acid molecule comprising: a first polycistronic cassette comprising: TFPI (EPI / LACI), EPCR (PROCR), and thrombomodulin (THBD); a second polycistronic cassette comprising: B2M HLA-E fusion pr

The application relates to the technical field of stress urinary incontinence treatment, and particularly discloses a traditional Chinese medicine composition for treating stress urinary incontinence, which is composed of the following raw medicinal materials in a weight ratio: 15g of raw astragalus, 15g of codonopsis, 15g of salvia miltiorrhiza, 10g of raspberry, 10g of immature bitter orange and 6g of bupleurum. The application is strictly designed according to a single-arm, single-center, clinical retrospective research, and an internationally commonly used urinary incontinence outcome index determination standard. The test result shows that, at the end of 4 weeks of treatment, 69 sample results show that the Qishizhiyi recipe combined with pelvic floor muscle training can significantly reduce the ICI-Q-SF score, the number of 24h urinary incontinence, and improve the I-QOL score, and the total effective rate reaches 89.86%, and there is no obvious toxic side effect. Through basic animal experiment research, it is shown that the Qishizhiyi recipe can significantly reduce collagen degradation, regulate hormone levels, reduce oxidative stress damage and inhibit cell apoptosis, and from the basic aspect, it is confirmed that the Qishizhiyi recipe has the effects of regulating connective tissue factors and hormone levels and inhibiting cell apoptosis.

Chimeric polypeptides comprising a soluble tissue factor and an antigen binding domain are provided.SOLUTION: Provided herein are single-chain chimeric polypeptides comprising (i) a first target binding domain, (ii) a soluble tissue factor domain, and (iii) a second target binding domain. Also provided herein are methods of using these single-chain chimeric polypeptides and nucleic acids encoding these single-chain chimeric polypeptides.SELECTED DRAWING: Figure 1

Provided herein are multi-chain chimeric polypeptides that include:(a) a first chimeric polypeptide including a first target-binding domain, a soluble tissue factor domain, and a first domain of a pair of affinity domains; and (b) a second chimeric polypeptide including a second domain of a pair of affinity domains and a second target-binding domain, where the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains. Also provided here are methods of using these multi-chain chimeric polypeptides and nucleic acids encoding these multi-chain chimeric polypeptides.

This invention provides a bispecific antibody targeting tissue factors, an antibody-drug conjugate (ADC), its preparation method, and its application, belonging to the field of biopharmaceutical preparation technology. The bispecific antibody provided by this invention can efficiently target tissue factors in tumor cells, exhibiting advantages such as strong affinity and high endocytosis efficiency. This invention also provides an ADC, which, under the action of the bispecific antibody, specifically binds to tumor surface antigens and is internalized into tumor cells, achieving precise drug delivery for antitumor drugs. The ADC provided by this invention exhibits good tumor-suppressing effects in both cell and animal models, and is non-toxic and harmless to animals, demonstrating excellent potential for cancer treatment.

The invention relates to a tissue factor binding antibody and application thereof, in particular to an antibody specifically binding to TF or an antigen binding fragment thereof and a kit containing the antibody or the antigen binding fragment, the antibody or the antigen binding fragment comprises (i) an LCDR1 sequence, an LCDR2 sequence and an LCDR3 sequence of a light chain variable region as shown in SEQ ID NO: 1 and (ii) an HCDR1 sequence, an HCDR2 sequence and an HCDR3 sequence of a heavy chain variable region as shown in SEQ ID NO: 2, the CDR is defined according to the IMGT, the Kabat, the Chothia, the Contact or any combination of the IMGT, the Kabat, the Chothia and the Contact. The tissue factor binding antibody provided by the invention has high sensitivity, high accuracy and high precision, and can meet the requirement of accurate detection of tissue factors.

This invention relates to the fields of biomedical engineering and regenerative medicine, and particularly to a plasma matrix composite membrane activated by autologous keratinized epithelial tissue fragments, its preparation method, and its applications. The composite membrane is obtained by mixing autologous keratinized epithelial tissue fragments with a liquid autologous plasma matrix in a specific ratio, utilizing tissue factors on the surface of the tissue fragments to trigger platelet activation, spontaneously forming a gel, and then pressing it into a membrane. This invention is the first to utilize the biointerface of autologous keratinized epithelial tissue fragments to activate platelets, eliminating the need for exogenous thrombin and achieving completely autologous in-situ gelation. The composite membrane formed after pressing possesses excellent mechanical properties and barrier function, and can be prepared in a single operation in the operating room without the need for in vitro cell culture. The composite membrane of this invention is used for oral soft tissue augmentation, such as widening of keratinized gingiva and alveolar ridge soft tissue augmentation, and has advantages such as no donor site damage, high biosafety, and ease of operation.

The present application relates to a kind of methods for screening active ingredients of salvia miltiorrhiza and chuanxiong as tissue factor inhibitors and purposes, comprising: according to the requirement of pharmacophore model construction, obtain small molecule compounds with inhibiting TF coagulation activity as data set, data set is split into training set and test set, construct pharmacophore with activity prediction ability;With the pharmacophore with activity prediction ability constructed from multiple active ingredients of salvia miltiorrhiza and chuanxiong Virtual screening active molecule, multiple small molecule compounds with inhibiting TF coagulation activity are screened;Determine the macromolecular compound of TF related protein from PDB database;Using molecular docking software, small molecule compounds with inhibiting TF coagulation activity are screened, and docking is carried out with the macromolecular compound of TF protein, the docking result is combined to form complex, and the result is visualized using Schrodinger, the purpose is to find new small molecule inhibitors, obtain TF inhibitor with good bioavailability.

The present invention belongs to the field of biotechnology engineering and provides a recombinant tissue factor (rhTF) mutant and its application. The recombinant tissue factor mutant is: rhTF mutant A, whose amino acid sequence is shown in SEQ ID NO.3 and whose mutation sites are simultaneously mutated: T17F, I22R, S47R, T112W, S188R, and V207R, and whose nucleotide sequence is shown in SEQ ID NO.4; or rhTF mutant B, whose amino acid sequence is shown in SEQ ID NO.5 and whose mutation sites are simultaneously mutated: T17F, I22R, S47F, T112W, S188K, and V207K, and whose nucleotide sequence is shown in SEQ ID NO.6. These mutants have high procoagulant activity and good thermal stability and are used in biomedicine, clinical prothrombin time determination, and wound hemostasis.

The present invention discloses a method for preparing a PT detection reagent, belonging to the technical field of detection reagents. The method comprises the following steps: step 1, extracting rabbit brain powder; step 2, centrifuging to obtain a supernatant; step 3, taking the supernatant and adding immobilized trypsin, stirring; step 4, vacuum filtration, removing the immobilized trypsin, and obtaining a PT reagent. The method for preparing the PT detection reagent comprises adding immobilized trypsin to a rabbit brain powder extract and stirring, allowing it to fully act, and then using a Buchner funnel to separate and remove it by vacuum filtration. The trypsin fully acts on the active particles (containing tissue factor and phospholipids) wrapped in agglomerates in the extract, cutting them into uniform and fine active particles. The increase in the number of active particles increases the activity of the reagent and improves the sensitivity of the reagent. After the active particles are small, they are evenly dispersed and difficult to precipitate, thereby improving the stability and making the liquid clear.